Emyria + Aspen Pharmacare Australia agreement for licensing and commercialisation (EMD-RX5)
Aspen Australia to support the registration and commercialisation of EMD-RX5
as an over-the-counter treatment in Australia.
"Aspen aims to be leaders in every product category we operate in. We are excited to continue this tradition by partnering with Emyria and supporting the registration and commercialisation of their unique product with large potential in the Australian market. We look forward to a long and successful partnership." - Aspen CEO, Trevor Ziman
Highlights of this announcement is here
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Emyria. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Emyria a question about this update.